Gogola Samantha, Rejzer Michael, Bahmad Hisham F, Alloush Ferial, Omarzai Yumna, Poppiti Robert
Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
Cancers (Basel). 2023 Mar 6;15(5):1621. doi: 10.3390/cancers15051621.
Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or a combination approach. In those with advanced disease, androgen deprivation therapy (ADT) is considered as a first-line therapy. However, the majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate cancer (CRPC). The near inevitable progression to CRPC has spurred the recent development of many novel medical treatments using targeted therapies. In this review, we outline the current landscape of stem-cell-targeted therapies for PCa, summarize their mechanisms of action, and discuss avenues of future development.
前列腺癌（PCa）是全球男性中第二常见的诊断出的癌症。在美国，它是根据国家综合癌症网络（NCCN）采用风险分层方法进行治疗的。早期PCa的主要治疗选择包括外照射放疗（EBRT）、近距离放疗、根治性前列腺切除术、主动监测或联合治疗方法。对于晚期疾病患者，雄激素剥夺疗法（ADT）被视为一线治疗。然而，大多数病例在接受ADT治疗时最终会进展，导致去势抵抗性前列腺癌（CRPC）。几乎不可避免地进展为CRPC促使了最近许多使用靶向疗法的新型医学治疗方法的发展。在这篇综述中，我们概述了目前针对PCa的干细胞靶向治疗的现状，总结了它们的作用机制，并讨论了未来的发展途径。
